The Amylin-GLP-1 Combination: Clinical Benchmarks for CagriSema
By GLPeak Team · 2026-05-19
CagriSema is redefining metabolic health. Discover how this dual-hormone injection targets hunger and fullness to outperform Wegovy and Zepbound in weight loss.
The landscape of metabolic health is currently witnessing the rise of a new class of combination therapies. Leading this charge is CagriSema, an investigational once-weekly injection from Novo Nordisk that combines two different hormones to tackle obesity and Type 2 diabetes.
As of early 2026, clinical trial data has painted a clearer picture of how this medication compares to current giants like Wegovy and Zepbound.
The Dual-Hormone Mechanism
CagriSema is a fixed-dose combination of two active ingredients: semaglutide (the active ingredient in Wegovy and Ozempic) and cagrilintide.
Semaglutide (GLP-1): This hormone focuses on slowing gastric emptying and signaling the brain to reduce hunger.
Cagrilintide (Amylin Analog): Amylin is a hormone co-secreted with insulin. It works by increasing feelings of fullness and further delaying how quickly the stomach clears.
By targeting both the hunger signals and the fullness signals simultaneously, CagriSema aims to provide an additive effect that exceeds what semaglutide can achieve on its own.
Key Research Findings from 2026
Recent readouts from the REDEFINE and REIMAGINE trial programs have provided significant benchmarks for the drug's performance.
Superiority Over Wegovy: In the REIMAGINE 2 trial involving adults with Type 2 diabetes, CagriSema achieved a 14.2% weight loss over 68 weeks, compared to 10.2% for those taking semaglutide alone. It also showed superior blood sugar control, reducing HbA1c levels by 1.9 percentage points.
The 23% Weight Loss Milestone: In the REDEFINE 4 trial, participants with obesity achieved an average weight loss of 23.0% after 84 weeks of treatment. This places CagriSema in a high-efficacy category that begins to rival the results typically seen in bariatric surgery.
Head-to-Head with Zepbound: In a direct comparison study, while CagriSema showed a robust 23% weight loss, it did not meet the "non-inferiority" mark against Eli Lilly’s Zepbound (tirzepatide), which showed a 25.5% reduction in the same 84-week window.
Safety and Tolerability
The safety profile of CagriSema appears consistent with the broader class of GLP-1 medications. The most common side effects reported in the 2026 data were gastrointestinal, including nausea, diarrhea, and vomiting.
Most of these symptoms were reported as mild to moderate and tended to decrease over time as the body adjusted to the medication. Because the drug includes two different mechanisms that slow digestion, the titration phase where a patient slowly increases the dose is expected to be a critical part of the treatment plan to manage these effects.
Future Outlook and Availability
Novo Nordisk submitted a New Drug Application to the FDA for CagriSema in December 2025. A regulatory decision is anticipated by late 2026.
Looking forward, researchers are already planning trials for a higher-dose version of CagriSema to see if it can push the weight loss ceiling even further. Additionally, the drug is being studied for its long-term impact on cardiovascular health and its potential to resolve fatty liver disease (MASH).
The Strategic Takeaway
The development of CagriSema marks a transition from single-target to multi-target obesity care within Novo's care options. While it may not have surpassed tirzepatide in every metric, it offers a powerful alternative for patients who may not tolerate other medications or who require the specific blood-sugar benefits of the amylin-GLP-1 combination.